Sanara MedTech (NASDAQ:SMTI) Lowered to Hold Rating by Freedom Capital

Freedom Capital cut shares of Sanara MedTech (NASDAQ:SMTI) from a strong-buy rating to a hold rating in a research report released on Monday,Zacks.com reports.

Several other analysts have also issued reports on the stock. Wall Street Zen lowered shares of Sanara MedTech from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sanara MedTech in a report on Friday, July 17th. Zacks Research upgraded shares of Sanara MedTech from a “strong sell” rating to a “hold” rating in a research note on Wednesday, June 10th. HC Wainwright cut shares of Sanara MedTech from a “buy” rating to a “neutral” rating and lowered their target price for the company from $36.00 to $35.00 in a report on Thursday, July 30th. Finally, Lake Street Capital downgraded Sanara MedTech from a “buy” rating to a “hold” rating and set a $35.00 target price on the stock. in a research report on Thursday. Four research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Sanara MedTech has an average rating of “Reduce” and a consensus price target of $35.00.

Sanara MedTech Price Performance

Shares of NASDAQ:SMTI opened at $34.00 on Monday. The company has a quick ratio of 2.05, a current ratio of 2.28 and a debt-to-equity ratio of 6.59. The firm has a market capitalization of $311.44 million, a PE ratio of -9.02 and a beta of 1.12. Sanara MedTech has a twelve month low of $16.05 and a twelve month high of $35.95. The company has a 50-day moving average price of $24.28 and a two-hundred day moving average price of $21.41.

Institutional Investors Weigh In On Sanara MedTech

A number of institutional investors and hedge funds have recently modified their holdings of SMTI. Royal Bank of Canada grew its stake in Sanara MedTech by 127.3% during the fourth quarter. Royal Bank of Canada now owns 117,643 shares of the company’s stock valued at $2,747,000 after acquiring an additional 65,887 shares in the last quarter. Marshall Wace LLP lifted its stake in Sanara MedTech by 144.3% in the 2nd quarter. Marshall Wace LLP now owns 71,511 shares of the company’s stock worth $2,030,000 after purchasing an additional 42,237 shares in the last quarter. Walleye Capital LLC purchased a new stake in Sanara MedTech in the 2nd quarter worth approximately $719,000. Renaissance Technologies LLC lifted its stake in Sanara MedTech by 72.0% in the 1st quarter. Renaissance Technologies LLC now owns 64,680 shares of the company’s stock worth $1,111,000 after purchasing an additional 27,078 shares in the last quarter. Finally, Squarepoint Ops LLC boosted its holdings in Sanara MedTech by 343.4% in the 3rd quarter. Squarepoint Ops LLC now owns 31,383 shares of the company’s stock valued at $996,000 after purchasing an additional 24,305 shares during the period. 8.10% of the stock is owned by hedge funds and other institutional investors.

Sanara MedTech Company Profile

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.